NSE: BETA | BSE: 531481

Slowing Down Stock

Download real time

1053.90 2.30 (0.22%)

New 52W Low in past week

14,780 NSE Volume

NSE 02 Mar, 2026 3:31 PM (IST)

1,063.9

Market Cap

Above industry Median

Beta 1Year

Low volatility

Beta Drugs Ltd. share price target and research reports

Name: Latest research reports of Beta Drugs Ltd. authored by Edelweiss and published by - Trendlyne research reports.
Item: Beta Drugs Ltd.
Rating: 5
Author: Edelweiss

Latest analyst research reports with target prices and PDF download for BETA, BSE:531481 Beta Drugs Ltd.

Search Inside the pdf :

Beta Drugs Ltd.

08 Nov 2024

1053.90

0.22%

Beta Drugs | H1FY25 Result Update

Buy: Beta Drugs Ltd.

Target

Edelweiss

Strong show in H1; near-term growth factored in

Beta Drugs has lost -44.53% in the last 6 Months

Beta Drugs Ltd.

16 May 2024

1053.90

0.22%

Beta Drugs Ltd | H2FY24 Result Update

Buy: Beta Drugs Ltd.

Target

Edelweiss

Deepening its roots in the market

Beta Drugs has lost -39.56% in the last 3 Months

Beta Drugs Ltd.

03 Sep 2023, 12:00AM

1053.90

0.22%

Beta Drugs | The CUB Series

Buy: Beta Drugs Ltd.

Edelweiss

Beta Drugs (BETADR) is one of the leading players in the domestic oncology space and ranks among the top 10 in the cytotoxic market.

Beta Drugs has lost -44.53% in the last 6 Months

Beta Drugs Ltd.

24 Mar 2023

1053.90

0.22%

Beta Drugs | Plant Visit Note

Not Rated: Beta Drugs Ltd.

Edelweiss

We visited Beta Drugs' (BETADR) formulation facilities located at Baddi and Mohali (Chandigarh), which have been expanded and upgraded, and the management.

Beta Drugs has lost -32.91% in the last 1 Year

Is Beta Drugs Ltd. worth buying?

68 Votes:

Buy 79.41%

Sell 11.76%

Hold 8.82%